Precis: Obstetric blood transfusions continue to increase, with most of these occurring in the birth admission in association with hemorrhage.
Introduction
Blood transfusion, as applies to any therapy, should be used judiciously and appropriately to ensure optimal patient outcomes. Blood is a limited, costly resource with transfusion of it or any of its products associated with specific risks. (1, 2) Internationally, this has lead to increased efforts to reduce unnecessary blood use across many disciplines. (12) and Ireland (0.84% in 2003). (11) Reasons for the higher rate are unknown, although may relate to differences in data collection. While for many surgical procedures, high risk of transfusion is known in advance, and measures to minimize the risk of transfusion can be taken, this is rarely the case in obstetrics, where transfusions tend to be urgent, unpredictable, and in otherwise healthy women. (13) A small number of population based studies have identified risk factors for blood transfusion in the maternity setting. Important risk factors include mode of delivery, placenta previa, antepartum hemorrhage, anemia, multiple pregnancies, and the extremes of maternal age. (10, 14, 15) Population data collected in administrative datasets provide a valuable source of data for such studies, allowing examination of trends and risk factors in uncommon outcomes such as transfusion. (16) These studies typically look only at the birth admission, and so are unable to estimate the transfusion burden associated with antenatal and postpartum hospitalizations.
Few studies have considered blood products other than red cells.
This study aims to explore recent trends in blood and blood product transfusion, and the use of blood products throughout pregnancy and the postnatal period in women whose pregnancy ended in a registered birth (beyond 20 weeks gestation). We also examine the risk factors for transfusion during the birth admission.
Materials and Methods
The study population included women giving birth in NSW hospitals between January 2001 and December 2010. NSW is the most populous state in Australia, with over 7 million residents and approximately 90,000 births per annum. 'Birth data' including maternal characteristics, pregnancy and birth were obtained from the Perinatal Data Collection (PDC).
The PDC is a statutory population based collection of all births in NSW of at least 20 weeks gestation or 400 grams birthweight. These data were linked to 'hospital data' from the Hospital admissions were classified as antenatal, birth or postnatal, to allow for examination of the different blood product usage at each stage of pregnancy. Antenatal admissions were those that occurred from 20 weeks gestation and ended with the mother being discharged prior to the birth. Birth admissions were separated into those with a prolonged antenatal component (>4 days), and those admitted 4 days or less before birth. Postnatal admissions were admissions occurring after the initial discharge of the mother, but within 6 weeks of the birth. Admissions involving transfusion of blood products were identified from the hospital data, using ACHI procedure codes. (17) 'Blood transfusion' refers to the administration of packed red cells or whole blood, and 'Platelets and coagulation factors' includes platelets, coagulation factors, and other serum (including fresh frozen plasma), 'Blood products' is used to refer to transfusion of either or both of these. Blood transfusion and administration of platelets and coagulation factors are well ascertained in the hospital data, with sensitivities and specificities of 83.1%, 99.9% and 73.1%, 100% respectively. (16) The quality of reporting of use of other blood derived products (including leukocytes, gamma globulin) is unknown and so use of these products was not considered. Women with iron deficiency anemia were identified from the hospital data and women with bleeding or platelet disorders were identified by ICD-10-AM codes for conditions such as thalassemia, hemolytic and aplastic anemias, coagulation defects, and idiopathic thrombocytopenic purpura (Appendix 1). Antepartum hemorrhage (APH) included placental abruption or other antepartum hemorrhage. Women without bleeding disorders, APH, placenta previa, hypertension and diabetes were considered to have no prior indication for transfusions. Age and gestational age groups were determined based on clinical relevance and women were classified as private patients if they received private obstetric care in a public or private hospital.
Rates were calculated per 100,000 pregnancies and proportions are proportion of pregnancies, unless otherwise specified. Multiple births (twins or higher order multiples) were counted as a single pregnancy. Trends were assessed using the Cochran Armitage test for trend. A multivariable Poisson regression model with robust variances was used to identify factors associated with higher use of blood product transfusions; factors which were significant with alpha 0.2 in a univariate model were included in the initial multivariable model, and removed in a stepwise fashion until only variables significant at alpha 0.05 remained. This was performed separately for vaginal and cesarean births to account for possible differences in decision making based on physical location (operating theatre versus birth unit), and differing criteria for PPH (a common indication for blood transfusion). In the ICD-10-AM PPH is defined as blood loss of 750mL or more following cesarean section, or When compared with red cell use, platelets and coagulation factors were more commonly used among women aged 35 and older, private patients, multiparous women and those having a cesarean birth (Table 1) . Where blood product transfusion occurred during pregnancy, this usually occurred in a single admission (98.6%), with less than 0.4% of pregnancies involving 3 or more admissions involving transfusions.
Rates of transfusion in the birth and postnatal period were high in women having a hysterectomy in the birth admission (89619 per 100,000 such pregnancies, N= 439), where blood products had been transfused antenatally (18750 per 100,000, N=63), and where a PPH occurred in the birth admission (13528 per 100,000, N=8388). In women with no prior indication, the transfusion rate was 953 per 100,000 pregnancies (N=6927). Among birth admissions with <4 days antenatal stay involving transfusion, 80.8% included a hemorrhage diagnosis. Women who received transfusions in birth or postnatal admission were in hospital longer than those who did not (median days (IQR) birth 5 (4,7) vs 3 (2,5), postnatal 3 (2,5) vs 2 (0,3)).
Full data on possible confounders were available for 885,389 pregnancies (99.3%) and were included in our risk factor analysis. Overall, after adjusting for maternal factors, forceps delivery was associated with the highest risk of transfusion of all modes of birth when compared with non-instrumental vaginal delivery, followed by intrapartum cesarean section, vacuum delivery and pre-labor cesarean section (Table 2) . Across both vaginal and cesarean births women with bleeding/platelet disorders or placenta previa were at increased risk of transfusion. Amongst vaginal births, forceps deliveries and multiple births were also associated with a more than doubling of the risk of transfusion, while amongst cesarean deliveries preterm births of <33 weeks gestation and antepartum hemorrhage were associated with a more than doubling of risk. Nulliparous women were at greater risk of transfusion when delivering vaginally, as were women with a previous cesarean ( Table 2) .
When included in the model, iron deficiency anemia was associated with an increased risk of transfusion (vaginal RR 7.1 (6.4,7.9); cesarean RR 4.5(3.9,5.6)), leaving other estimates largely unchanged. However, identification of women with iron deficiency anemia has low sensitivity (5.7-12.0%) (19) and so this was excluded from the final model. Another possible reason for the increase in transfusion is the recent increase in PPH, which has been observed both in NSW (24) and overseas. (6, 8, 11, 12) As the majority of transfusions are performed in admissions with a diagnosis of hemorrhage, an increase in PPH would likely lead to an increase in blood transfusions, as has been observed elsewhere. (8, 9) Similar to transfusion generally, this increase in PPH is not able to be fully accounted for by the change in maternal characteristics. (12, 24) The increase in transfusion is also possibly linked to increased severity of PPH. In both Ireland and Canada there have been reports of increasing severity of PPH. (9, 11) The increase in transfusion rates may also reflect a change in practice, with clinicians using less restrictive criteria for transfusion than in the past, rather than reflecting an increase in severity of bleeding. We were unable to assess changes in transfusion thresholds, however there has been growing awareness of risks associated with transfusion, and concerns over the future availability and cost of blood.(1, 2) Against this background, it would be expected that changing practice should reduce rather than increase transfusion rates. Interestingly, the slight dip in transfusion rates in 2008 coincided with a statewide initiative to decrease obstetric transfusions,(25) however this decline was not maintained.
Discussion
Similar to other studies, we found increased risk of transfusion associated with bleeding and platelet disorders,(26) placenta previa, (15, 27) antepartum hemorrhage,(10, 15) multiple births,(28) primparous women,(10, 27, 28) large birthweight, (10, 28) and maternal hypertension. (10, 15) Vaginal birth after cesarean carried a higher risk of transfusion than repeat cesarean. (10, 15, 28) Preterm birth was also associated with higher rates of transfusion, which has been demonstrated elsewhere, (27) and is possibly related to anemia which is a risk factor for preterm birth and transfusion. (29) It should be noted that while bleeding and platelet disorders were associated with seven to nine times the risk of transfusion, the overall population burden of this group is small, due to the rarity of these conditions.
We found both instrumental and cesarean delivery were associated with an increased risk of transfusion. There were higher transfusion rates following forceps deliveries than vacuum deliveries, and higher rates following intrapartum than pre-labor cesarean sections. Cesarean section had higher risk of transfusion than non-instrumental vaginal delivery, as has been reported elsewhere, (10, 15, 27) with this risk increased if the cesarean section was performed after the onset of labor. A Danish study, however, found that planned cesarean section had a lower risk of transfusion than a planned vaginal birth, although the 'planned vaginal birth' group included women who had instrumental births and intrapartum cesarean sections. (28) We found the rate of transfusion to be much lower in private hospitals compared with public, which is consistent with lower risk women giving birth in appropriate settings. (30) (31) (32) In Australia, tertiary obstetric care is only available in public hospitals. Tertiary hospitals had the highest rates of transfusion of platelets and coagulation factors, which may reflect increased complexity of cases in these hospitals. Alternatively higher blood product use in tertiary settings could reflect better access to products in the larger centers. Blood product use was more common with older mothers, private patients (particularly those in public hospitals), multiparous women and those having a cesarean birth. Without information on severity of bleeding it is difficult to know the significance of these findings. Platelets and coagulation factors are usually transfused in cases of severe bleeding in order to replace lost clotting factors, (33) and are typically included as part of a massive transfusion protocol. (34) The increased use of blood products observed may reflect increased severity of hemorrhage amongst these women. 
